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Key questions
What is already known about this subject?
 ► Human epidermal growth factor receptor 3 (HER3) is 
associated with tumour development and poor clini-
cal prognosis in different cancers.
 ► HER3 ligand heregulin may serve as a response pre-
diction marker for HER3-targeting therapy.
 ► Heregulin expression levels are higher and more 
frequent in squamous non-small cell lung cancer 
(sqNSCLC).
What does this study add?
 ► HER3-targeting lumretuzumab in combination with 
carboplatin and paclitaxel was well tolerated.
 ► High heregulin expression levels enriched for pa-
tients more likely to show a clinical response.
 ► Clinically meaningful contribution to efficacy by lum-
retuzumab could not be demonstrated as compared 
with chemotherapy and immunotherapy.
How might this impact on clinical practice?
 ► HER3-targeting therapy may not add meaningful 
clinical benefit as to what has been shown for plati-
num-containing treatment regimens in the first-line 
treatment setting of sqNSCLC.
AbstrAct
Purpose This study investigated the safety and clinical 
activity of lumretuzumab, a humanised antihuman 
epidermal growth factor receptor 3 (HER3) monoclonal 
antibody, in combination with carboplatin and paclitaxel 
in first-line treatment of patients with squamous non-
small cell lung cancer (sqNSCLC). HER3 ligand heregulin 
and HER3 protein expression were evaluated as potential 
biomarkers of clinical activity.
Patients and methods This open-label, phase Ib/II study 
enrolled patients receiving lumretuzumab at 800 mg 
(flat) in combination with carboplatin (area under the 
curve (AUC) 6 mg/mL×min) and paclitaxel (200 mg/m2) 
administered intravenously on a every 3-week schedule. 
Adverse event (AE) rates and tumour responses were 
determined. Heregulin messenger RNA (mRNA) and HER3 
protein expression were investigated in archival tumour 
biopsies.
Results Altogether, 12 patients received lumretuzumab 
in combination with carboplatin and paclitaxel. The most 
frequent AEs were gastrointestinal, haematological and 
nervous system toxicities, which were generally mild and 
manageable. Partial responses were observed in 3 of 12 
patients lasting 81, 177 and 207 days. All responses were 
achieved in tumours expressing higher heregulin mRNA 
levels.
Conclusion Lumretuzumab in combination with 
carboplatin and paclitaxel was well tolerated. Objective 
responses were enriched in tumours expressing higher 
heregulin mRNA levels.
IntRoduCtIon
Lung cancer is one of the most frequent types 
of cancer worldwide both in terms of cases 
(2.1 million cases, 11.6% of total) and deaths 
(1.8 million deaths, 18.4%).1 Among lung 
cancer subtypes, non-small cell lung cancer 
(NSCLC) is the most prevalent and about 
30% of NSCLC are squamous (sqNSCLC) 
cell carcinomas. Approximately 80% of lung 
cancer cases are diagnosed at stages III and 
IV.2
Until the advent of cancer immuno-
therapy, that is, checkpoint inhibition, plat-
inum-based combination chemotherapy was 
the standard of care in patients with newly 
diagnosed advanced/metastatic sqNSCLC.3 
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factor receptor (EGFR) inhibitors and anaplastic 
lymphoma kinase (ALK) inhibitors have shown clin-
ical efficacy in molecular subgroups such as EGFR-mu-
tant and ALK-rearranged NSCLC particularly of the 
non-squamous subtype4–6 but less so for all-comers 
treated with cetuximab, cisplatin and vinorelbine7 or 
for patients with sqNSCLC treated with necitumumab, 
gemcitabine and cisplatin.8 In the meantime, phase 
III studies have established antiprogrammed cell-
death protein 1 (ligand) (PD-(L)1) compounds as the 
new standard of care in both sqNSCLC and non-squa-
mous NSCLC. Pembrolizumab monotherapy has been 
approved as first-line therapy for patients with high 
PD-L1 expression (≥50%)9 and for non-squamous 
histology in combination with platinum and peme-
trexed10 and also for squamous histology in combination 
with carboplatin together with paclitaxel or nab-pacli-
taxel11 independently of PD-L1 expression.
HER3 is a key dimerisation partner of HER family 
members which activates several signal transduction path-
ways, particularly the phosphoinositide-3-kinase (PI3K)/
Akt pathway and is associated with tumour develop-
ment and poor clinical prognosis in different cancers.12 
Lumretuzumab is a humanised, glycoengineered immu-
noglobulin G1 antibody which binds with high affinity 
and specificity to the extracellular domain of HER3. 
Prevention of the ligand heregulin binding to HER3 by 
lumretuzumab resulted in almost complete inhibition of 
HER3 heterodimerisation and phosphorylation as well 
as inhibition of tumour growth in cell-line-based mouse 
models.13 In a phase I study, the safety of lumretuzumab 
in patients with advanced solid tumours was evaluated; no 
dose-limiting toxicity was observed at doses up to 2000 
mg every 2 weeks and the maximum tolerated dose was 
not reached. Lumretuzumab doses from 200 mg led to 
downregulation of membranous HER3 and a target-inde-
pendent pharmacokinetic profile was observed from 400 
mg doses and above.14
HER3 is widely expressed in NSCLC including 
sqNSCLC.15 16 In addition, higher expression levels of 
heregulin, the ligand of HER3, were associated with 
improved antitumour efficacy in preclinical models.17–19 
Internal data from tumour bank samples as well as 
published data20 provided evidence that heregulin expres-
sion levels are higher and more frequent in sqNSCLC 
as compared with NSCLC adenocarcinoma. Hence, we 
hypothesised that deprivation of HER3/PI3K-mediated 
cell survival signals by HER3-targeting lumretuzumab 
might provide improved treatment benefit especially in 
patients with sqNSCLC. At the time of study initiation, 
carboplatin and paclitaxel were considered a standard of 
care with an objective response rate of ~25%.21 Therefore, 
carboplatin and paclitaxel were included as backbone 




The study reported here was a phase Ib/II, open-label, 
non-randomised, multicentre study ( ClinicalTrials. gov 
Identifier: NCT02204345) of lumretuzumab in combina-
tion with paclitaxel and carboplatin in patients with meta-
static or advanced sqNSCLC. The primary objectives of 
the study were to evaluate the safety and tolerability of 
lumretuzumab in combination with carboplatin and pacl-
itaxel and to estimate the efficacy of the combination, as 
measured by the objective response rate (ORR, defined as 
complete response (CR) rate+partial response (PR) rate).
As previously shown, pharmacokinetics of lumretu-
zumab was linear from ≥400 mg per patient, indica-
tive of saturated target-mediated drug disposition, and 
maximum pharmacodynamic activity was reached in 
monotherapy ≥400 mg 14. Therefore, a dose of 800 mg 
was defined as a fixed dose of lumretuzumab in this study.
ethics
All patients provided written informed consent. The study 
was conducted in accordance with Good Clinical Practice 
guidelines and the Declaration of Helsinki in five centres 
in Spain, Canada and Denmark.
Patients
Patients had a histologically confirmed diagnosis of 
advanced or metastatic (stage IIIb or IV22) sqNSCLC. 
Patients had not received prior chemotherapy or targeted 
therapy for NSCLC. Eligible patients were ≥18 years 
of age, had an Eastern Cooperative Oncology Group 
(ECOG) performance status of 0–1 and had adequate 
haematology, blood chemistry and renal and liver func-
tion. Prior radiotherapy to control local symptoms was 
allowed if target lesions outside the radiotherapy field 
existed. Patients eligible for enrolment had to provide 
archival tumour biopsy tissue or underwent a fresh 
(pretreatment) tumour biopsy that was used to assess the 
level of HER3 protein expression by immunohistochem-
istry (IHC) and central pathology review.
study drug administration
All patients were administered 800 mg of lumretuzumab 
intravenously in combination with 6 mg/mL×min AUC 
of carboplatin and 200 mg/m2 of paclitaxel every 3 
weeks for 4–6 cycles. Thereafter, patients could receive 
lumretuzumab as a monotherapy (carboplatin and pacl-
itaxel could be continued at the investigator’s discretion) 
until disease progression, death, unacceptable toxicity, 
withdrawal of consent or at the investigator’s decision, 
whichever occurred first. For carboplatin and paclitaxel, 
premedication was administered according to the manu-
facturer’s instructions. For lumretuzumab, no premedi-
cation was foreseen prior to the first administration but 
could be introduced for subsequent cycles based on the 
patient’s tolerability.
tumour response and safety
Tumour response assessment using Response Evalua-
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Table 1 Baseline patient demographics and characteristics
Characteristic Patients (N=12)
Sex, n (%)
  Male 10 (83.3)
  Female 2 (16.7)
Age (years), median (range) 66.5 (52–74)
ECOG score, n (%)
  0 5 (41.7)
  1 7 (58.3)
Prior radiotherapy, n (%) 2 (16.7)
Prior surgery, n (%) 0
ECOG, Eastern Cooperative Oncology Group.
screening and every 6 weeks thereafter by the investiga-
tors. CRs and PRs had to be confirmed with a second 
assessment.
Safety assessments included physical (ECOG perfor-
mance status, vital signs) and laboratory examinations 
and ECG. AEs were defined according to the Common 
Terminology Criteria for Adverse Events, V.4.0 (CTCAE 
V.4.0).
Biomarker assessments
Squamous cell carcinoma antigen (SCC) and cytoker-
atin fragment (CYFRA) 21-1 from peripheral blood were 
locally assessed by immunoassay every 6 weeks.
Fresh or archival tumour biopsies were collected 
during screening. HER3 protein expression was assessed 
using an IHC assay as described previously14. Heregulin 
mRNA expression was measured by quantitative real-time 
PCR assay, as a potential predictive biomarker for lumre-
tuzumab activity, in formalin-fixed paraffin-embedded 
(FFPE) sections obtained from fresh tumour biopsies 
collected from all patients at screening prior to initiation 
of treatment.24 A prototype diagnostic assay was used for 
which reagents were prepared in a good manufacturing 
practice facility, the assay run using a z480 PCR system 
and calculation of Ct values was performed using vali-
dated diagnostic software (Q2 Solutions (Livingston, 
UK)). Patients were assigned as having high heregulin, if 
mRNA concentrations were greater than median hereg-
ulin expression previously determined using 150 primary 
FFPE tumour biopsy samples obtained from patients diag-
nosed with sqNSCLC.
statistical considerations
All patients who received at least one dose of study medi-
cation were included in the statistical analyses. Descriptive 
statistics were used for demographics and safety as well 
as efficacy. In addition, in order to explore the relation 
between heregulin levels and response as well as whether 
responders and non-responders have different tumour 
marker dynamics, additional plots are shown.
Results
Patients
Patient demographics and baseline characteristics 
are presented in table 1. Altogether, 12 patients were 
enrolled. None of them had prior surgery for their disease 
and only two patients (16.7%) had prior radiotherapy. 
All 12 patients (100%) received at least one dose of the 
study treatment. The most common reason for discon-
tinuation from the study was disease progression (9/12 
patients (75%)). Other reasons for discontinuation were 
AE (general physical health deterioration; 1/12 patients 
(8.3%)), physician decision (1/12 patients (8.3%)) 
and other reason (1/12 patients (8.3%)). The median 
number of treatment cycles administered per patient was 
5.5 cycles (range 1–16) for lumretuzumab and four cycles 
(range 1–6) for both carboplatin and paclitaxel. HER3 
was present on tumour cells in 9/12 patients (75%), 
although median expression was low (mean immunore-
active score (IRS): 0.25, range 0–1.47). HER3 expression 
was not detectable by IHC in 2/3 (66%) patients with a 
PR.
safety
All 12 patients (100%) experienced at least one AE in the 
study (table 2). There were no deaths due to AEs. The 
most common AEs (>40% of patients) were diarrhoea 
(9/12 patients (75%)), asthenia (8/12 patients (66.7%)) 
and neurotoxicity (5/12 patients (41.7%)). Five of 
12 patients (41.7%) had nine AEs of CTCAE grade 3 
(anaemia (two events), neutropenia (two events), throm-
bocytopenia; respiratory tract infection, loss of conscious-
ness, dyspnoea and general physical health deterioration 
(one event each)). Two patients also experienced two 
AEs of grade 4 (neutrophil count decreased and platelet 
count decreased). One of 12 patients (8.3%) had an AE 
(deterioration of general physical health, considered 
unrelated to lumretuzumab) leading to withdrawal from 
the study treatment. A total of 3/12 patients (25%) expe-
rienced four serious adverse events (SAEs). The four SAEs 
were respiratory tract infection and loss of consciousness 
experienced by one patient and infected neoplasm and 
dyspnoea experienced by one patient each all considered 
unrelated to study treatment.
Antitumour activity
The ORR and disease control rate (DCR) were 25% 
(90% CI 4.44 to 45.56) and 91.7% (90% CI 78.54 to 100), 
respectively (table 3). The best response was a PR seen in 
3/12 patients (25%), and 8/12 patients (75%) had stable 
disease as a best response (figure 1). The median dura-
tion of PFS was 122 days (95% CI 81 to 217) with 10/12 
patients (83.3%) showing disease progression during 
the study. There were 2/12 patients (16.7%) without any 
progression events, who were censored from the analysis 
of progression-free survival (PFS). The duration of the PR 
in patients was 81, 177 and 207 days, respectively. Tumour 
shrinkage in patients was accompanied by decreasing 
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Table 2 Summary of adverse events of any grade and of 
grade ≥3 adverse events
Adverse event
Patients (n) having an 
adverse event (%) (N=12)
All grades Grade ≥3
Diarrhoea 9 (75.0) 0
Asthenia 8 (66.7) 0
Platelet count decreased 5 (41.7) 2 (16.7)
Neurotoxicity 5 (41.7) 0
Infusion-related reaction* 4 (33.3) 0
Nausea 4 (33.3) 0
Neutropenia 3 (25.0) 2 (16.7)
Anaemia 3 (25.0) 2 (16.7)
Dyspnoea 3 (25.0) 1 (8.3)
Respiratory tract infection 3 (25.0) 1 (8.3)
Constipation 3 (25.0) 0
Weight decreased 3 (25.0) 0
Decreased appetite 3 (25.0) 0
Alopecia 3 (25.0) 0
Insomnia 3 (25.0) 0
Rash 3 (25.0) 0
Abdominal pain 2 (16.7) 0
Abdominal pain upper 2 (16.7) 0
Stomatitis 2 (16.7) 0
Vomiting 2 (16.7) 0
Fatigue 2 (16.7) 0
Musculoskeletal pain 2 (16.7) 0
Pain in the extremity 2 (16.7) 0
Hypomagnesemia 2 (16.7) 0
Only adverse events reported by >10% of the patients are shown.
*Four patients had infusion-related reactions; three of which the 
investigator considered as related to lumretuzumab and one 
patient had an infusion-related reaction related to paclitaxel.







Objective response rate, N (%) 0 3 (42.9) 3 (25.0)
Disease control rate, N (%) 4 (80.0) 7 (100) 11 (91.7)
PFS, median (95% CI), days 100 (38, 196) 122 (65, 217) 122 (81, 217)
HRG, heregulin;PFS, progression-free survival; RECIST, response evaluation criteria in solid tumours.
Figure 1 Best percentage change from baseline in sum of 
target lesions.
Heregulin mRnA–response relationships
Heregulin mRNA expression and response evaluation 
criteria in solid tumours response data was available for all 
patients (figure 3). Seven patients were considered hereg-
ulin high using the median ΔCt as a cut-off, determined 
from the analysis of a cohort of 150 FFPE tumour samples 
from patients with sqNSCLC as reported previously.24 
All three patients with a PR were in the heregulin-high 
group. Hence, the ORR in the heregulin-high population 
was 42.9%, the DCR was 100% (7/7 patients) and the 
median PFS (95% CI) was 122 (65 to 217) days compared 
with an ORR of 0% (0/5 patients), a DCR of 80.0% (4/5 
patients) and a median PFS (95% CI) of 100 (38 to 196) 
days for the remaining heregulin-low patients.
dIsCussIon
This is the first study to describe the combination of an 
anti-HER3 monoclonal antibody, lumretuzumab, with 
standard-of-care chemotherapy, that is, paclitaxel and 
carboplatin, as a first-line treatment for patients with 
sqNSCLC. In addition, the study aimed to generate 
signals in patients with elevated heregulin expression 
levels.
Overall, the safety profile of lumretuzumab in combi-
nation with carboplatin and paclitaxel in patients with 
advanced sqNSCLC is acceptable and consistent with 
carboplatin/paclitaxel chemotherapy toxicities. The 
most common AEs in this study were gastrointestinal, 
haematological and nervous system toxicities similar to 
the well-known side effects of carboplatin/paclitaxel 
chemotherapy alone.25–28 The addition of lumretu-
zumab to carboplatin and paclitaxel may have caused 
an increase in the incidence of diarrhoea compared 
with chemotherapy alone. Overall, this combination 
appeared to be tolerable as the median number of 
cycles given for chemotherapy was similar to the one 
seen by others.25 26 28 An increased incidence of diar-
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Figure 2 Tumour marker dynamics: percentage change 
from baseline, measured in plasma.
Figure 3 Objective response and HRG mRNA log 
expression in patients with first-line sqNSCLC (n=12). Green 
indicates partial response; blue indicates stable disease 
and red indicates progressive disease. HRG mRNA log 
expression determined using the prototype diagnostic 
assay. HER3, human epidermal growth factor receptor 3; 
HRG, heregulin; PR, partial response; mRNA, messenger 
RNA; sqNSCLC, squamous non-small cell lung cancer.
monotherapy and combinations of lumretuzumab 
with cetuximab, erlotinib and pertuzumab.14 24 29 An 
increased incidence of diarrhoea was also observed with 
other HER3-targeting agents, seribantumab and patri-
tumab, when combined with erlotinib, for the treat-
ment of NSCLC in phase II studies.30 31 Nevertheless, 
no diarrhoea grade ≥3 event has been reported for the 
combination of lumretuzumab with chemotherapy in 
the present study.
The efficacy seen with the combination of lumretu-
zumab in combination with carboplatin and paclitaxel, 
ORR=25% and a median PFS=122 days, is similar to 
what has been published for chemotherapy alone in 
recent phase III studies.25–28 Certainly, due to the low 
number of patients treated in this study, the efficacy 
data should be interpreted cautiously.
Clinical phase II studies using HER3-targeting ther-
apies32–37 have suggested heregulin mRNA expression 
levels as a response-predictive biomarker for HER3-tar-
geting therapy. In particular, patients with sqNSCLC 
have been shown to express higher levels of heregulin 
per se.20 Indeed, all three partial responders described 
in this study were considered to have higher heregulin 
expression levels; hence, the level of heregulin expres-
sion may enrich for patients with objective responses 
and a higher DCR. However, the number of patients 
responding to treatment were too small to draw firm 
conclusions in this regard and duration of response 
in patients with high tumour heregulin levels was in 
the range of what can be expected for chemotherapy 
alone.38 This is in line with phase II studies in NSCLC, 
colorectal cancer and head and neck cancer that could 
not show any treatment benefit of HER3-targeting ther-
apies in heregulin-high subgroups.31 39 40 An ongoing 
phase II study of HER3-targeting seribantumab in 
combination with docetaxel or pemetrexed in second 
to third-line treatment, prospectively heregulin-pos-
itive tested and selected patients with NSCLC might 
shed more light on this issue.41 The clinical activity in 
this small phase I patient set is overall inferior to the 
recent phase III trials including checkpoint inhibition 
in advanced/metastatic NSCLC. Pembrolizumab mono-
therapy in patients with PD-L1 expression (≥50%) with 
sqNSCLC or non-squamous NSCLC achieved an ORR 
of 44.8%,9 pembrolizumab in combination with chemo-
therapy in patients with sqNSCLC had an ORR of 57.9% 
with a median duration of response of 7.7 months11 and 
atezolizumab in combination with chemotherapy in 
patients with sqNSCLC showed an ORR of 49% and a 
median duration of response of 7.2 months.38 Eventu-
ally, the present data and the outcome of a sister study 
testing the combination of lumretuzumab plus erlotinib 
in patients with metastatic/advanced NSCLC showing 
similar limited efficacy24 led to the decision not to 
execute the phase II portion of this study.
In conclusion, combination treatment of lumretu-
zumab with carboplatin and paclitaxel was well toler-
ated, but clinically meaningful contribution to efficacy 
by lumretuzumab could not be demonstrated. High 
heregulin expression levels may be used to enrich for 
patients more likely to benefit, although the number 
of patients responding to treatment were too small to 
verify this hypothesis. Overall, the results of the present 
study indicate that HER3 is not a strong enough driver 
for sqNSCLC to warrant further clinical development of 
lumretuzumab in this indication.
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